Safety of repeated low-level red-light therapy for myopia: A systematic review
Chen Y, Xiong R, Yang S, Zhu Z, Li H, Xiang K, Congdon N, Wang W, He M
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) · 17 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2024-11-01 · Asia Pac J Ophthalmol (Phila) · vol. 13 · número 6 · pág. 100124
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 31 citas · más que el 94% de estudios similares · 3.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 93 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Ophthalmology and Visual Impairment Studies · Laser Applications in Dentistry and Medicine · Retinal Diseases and Treatments
- Palabras clave
- Medicine, Optometry
- MeSH
- humans, myopia, tomography, optical coherence, refraction, ocular, visual acuity, low-level light therapy
9 autores
- Yanping Chen🇨🇳Sun Yat-sen University
- Ruilin Xiong🇨🇳Sun Yat-sen University
- Shaopeng Yang🇨🇳Sun Yat-sen University
- Ziyu Zhu🇨🇳Sun Yat-sen University
- Hongyan Li🇨🇳Sun Yat-sen University
- Kaidi Xiang🇨🇳Shanghai Eye Disease Prevention & Treatment Center
- Nathan G. Congdon🇨🇳Sun Yat-sen University
- Wei Wang🇨🇳Sun Yat-sen University
- Mingguang He🇦🇺Centre for Eye Research Australia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Establishing the safety profile of repeated low-level red-light (RLRL) therapy is necessary prior to its widespread clinical implementation.
Methods
We conducted a systematic review (International Prospective Register of Systematic Reviews, CRD42024516676) of articles across seven databases from inception through February 10, 2024, with keywords related to myopia and RLRL therapy. Pooled safety outcomes and risk-to-benefit ratios were reported, and incidence of side effects was compared with other antimyopia interventions.
Results
Among 689 screened articles, 20 studies (2.90 %; median duration 9 months, longest 24 months) were analysed, encompassing 2380 participants aged 3-18 years and 1436 individuals undergoing RLRL therapy. Two case reports described an identical patient with reversible decline in visual acuity and optical coherence tomography (OCT) abnormalities, completely resolved 4 months after treatment cessation. No cases of permanent vision loss were reported. Temporary afterimage was the most common ocular symptom following treatment, resolving within 6 minutes in reported studies. The number needed to harm outweighed the number needed to treat by a ratio of 12.7-21.4 for a person with -3D to -8D myopia treated with RLRL therapy. Incidence of side effects from RLRL was 0.088 per 100 patient-years (95 % confidence interval, 0.02-0.50).
Conclusions
No irreversible visual function loss or ocular structural damage was identified with RLRL. Fundus photography and OCT before and during therapy, alongside home monitoring of visual acuity and duration of afterimages, are necessary to identify side effects. Further adequately powered studies of longer duration are needed to evaluate long-term safety of RLRL.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.